FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Ravdin

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Emiel Rutgers; Alastair M Thompson; Laura Van 't Veer; Giuseppe Viale; Anita Vindevoghel; Gustavo Werutsky; Suzette Delaloge; Ulrike Nitz; Rodolfo Passalacqua; Martine J Piccart-Gebhart; Jean-Yves Pierga; Peter M Ravdin; Isabel Teresa Rubio; Jan Bogaerts; Fatima Cardoso
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
David L Rimm; Torsten O Nielsen; Scott D Jewell; Daniel C Rohrer; Gloria Broadwater; Frederic Waldman; Kisha A Mitchell; Baljit Singh; Gregory J Tsongalis; Wendy L Frankel; anthony magliocco; Jonathan F Lara; Eric D Hsi; Ira J Bleiweiss; Sunil S Badve; Beiyun Chen; Peter M Ravdin; Richard L Schilsky; Ann D Thor; Donald A Berry
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.
Stella Mook; Laura J Van 't Veer; Emiel J Rutgers; Peter M Ravdin; Anthonie O van de Velde; Flora E van Leeuwen; Otto Visser; Marjanka K Schmidt
Independent prognostic value of screen detection in invasive breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Ravdin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Emiel Rutgers; Alastair M Thompson; Laura Van 't Veer; Giuseppe Viale; Anita Vindevoghel; Gustavo Werutsky; Suzette Delaloge; Ulrike Nitz; Rodolfo Passalacqua; Martine J Piccart-Gebhart; Jean-Yves Pierga; Peter M Ravdin; Isabel Teresa Rubio; Jan Bogaerts; Fatima Cardoso
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
European journal of cancer (Oxford, England : 1990) 2011;47(18):2742-9.
2011: David L Rimm; Torsten O Nielsen; Scott D Jewell; Daniel C Rohrer; Gloria Broadwater; Frederic Waldman; Kisha A Mitchell; Baljit Singh; Gregory J Tsongalis; Wendy L Frankel; anthony magliocco; Jonathan F Lara; Eric D Hsi; Ira J Bleiweiss; Sunil S Badve; Beiyun Chen; Peter M Ravdin; Richard L Schilsky; Ann D Thor; Donald A Berry
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2282-90.
2011: Stella Mook; Laura J Van 't Veer; Emiel J Rutgers; Peter M Ravdin; Anthonie O van de Velde; Flora E van Leeuwen; Otto Visser; Marjanka K Schmidt
Independent prognostic value of screen detection in invasive breast cancer.
Journal of the National Cancer Institute 2011;103(7):585-97.
2010: Song Yao; William E Barlow; Kathy S Albain; Ji-Yeob Choi; Hua Zhao; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Gabriel N Hortobagyi; Daniel F Hayes; Christine B Ambrosone
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(24):6169-76.
2010: Song Yao; William E Barlow; Kathy S Albain; Ji-Yeob Choi; Hua Zhao; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Gabriel N Hortobagyi; Daniel F Hayes; Christine B Ambrosone
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Breast cancer research and treatment 2010;124(2):433-9.
2010: Rowan T Chlebowski; Garnet L Anderson; Margery Gass; Dorothy S Lane; Aaron Aragaki; Lewis H Kuller; JoAnn E Manson; Marcia L Stefanick; Judith K Ockene; Gloria E Sarto; Karen C Johnson; Jean Wactawski-Wende; Peter M Ravdin; Robert Schenken; Susan Hendrix; Aleksandar Rajkovic; Thomas E Rohan; Shagufta Yasmeen; Ross L Prentice
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
JAMA : the journal of the American Medical Association 2010;304(15):1684-92.
2010: Peter M Ravdin
The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.
Cancer prevention research (Philadelphia, Pa.) 2010;3(6):686-8.
2010: Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Ki67 in breast cancer: prognostic and predictive potential.
The lancet oncology 2010;11(2):174-83.
2010: Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter M Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
The lancet oncology 2010;11(1):55-65.
2009: Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burton; Steven J Ketchel; Charles D Cobau; Ellis G Levine; James N Ingle; Kathleen I Pritchard; Allen S Lichter; Daniel J Schneider; Martin D Abeloff; I Craig Henderson; Hyman Muss; Stephanie J Green; Danika Lew; Robert B Livingston; Silvana Martino; C Kent Osborne
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Lancet 2009;374(9707):2055-63.
2009: Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5700-6.
2009: Jeanne S Mandelblatt; Kathleen A Cronin; Stephanie Bailey; Donald A Berry; Harry J de Koning; Gerrit Draisma; Hui Huang; Sandra J Lee; Mark Munsell; Sylvia K Plevritis; Peter M Ravdin; Clyde Schechter; Bronislava Sigal; Michael A Stoto; Natasha K Stout; Nicolien T van Ravesteyn; John Venier; Marvin Zelen; Eric J Feuer
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.
Annals of internal medicine 2009;151(10):738-47.
2009: Stella Mook; Marjanka K Schmidt; Emiel J Rutgers; Anthonie O van de Velde; Otto Visser; Sterre M Rutgers; Nicola Armstrong; Laura J van't Veer; Peter M Ravdin
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
The lancet oncology 2009;10(11):1070-6.
2009: Christine B Ambrosone; William E Barlow; Wanda Reynolds; Robert B Livingston; I-Tien Yeh; Ji-Yeob Choi; Warren Davis; James M Rae; Li Tang; Laura R Hutchins; Peter M Ravdin; Silvana Martino; C Kent Osborne; Alan P Lyss; Daniel F Hayes; Kathy S Albain
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):4973-9.
2009: D Craig Allred; Robert W Carlson; Donald A Berry; Harold J Burstein; Stephen B Edge; Lori J Goldstein; Allen Gown; M Elizabeth Hammond; James Dirk Iglehart; Susan Moench; Lori J Pierce; Peter M Ravdin; Stuart J Schnitt; Antonio C Wolff
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7 Suppl 6():S1-S21; quiz S22-3.
2009: Kathleen A Cronin; Peter M Ravdin; Brenda K Edwards
Sustained lower rates of breast cancer in the United States.
Breast cancer research and treatment 2009;117(1):223-4.
2009: Ji-Yeob Choi; William E Barlow; Kathy S Albain; Chi-Chen Hong; Javier G Blanco; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Daniel F Hayes; Christine B Ambrosone
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5258-66.
2009: Yu Shen; Wenli Dong; Barry W Feig; Peter M Ravdin; Richard L Theriault; Sharon H Giordano
Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.
Cancer 2009;115(10):2041-51.
2009: Jeffrey S Ross; Elzbieta A Slodkowska; W Fraser Symmans; Lajos Pusztai; Peter M Ravdin; Gabriel N Hortobagyi
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
The oncologist 2009;14(4):320-68.
2009: Rowan T Chlebowski; Lewis H Kuller; Ross L Prentice; Marcia L Stefanick; JoAnn E Manson; Margery Gass; Aaron Aragaki; Judith K Ockene; Dorothy S Lane; Gloria E Sarto; Aleksandar Rajkovic; Robert Schenken; Susan Hendrix; Peter M Ravdin; Thomas E Rohan; Shagufta Yasmeen; Garnet Anderson
Breast cancer after use of estrogen plus progestin in postmenopausal women.
The New England journal of medicine 2009;360(6):573-87.
2008: Lucy R Webster; Shu-Fen Lee; Clare Ringland; Adrienne L Morey; Andrew M Hanby; Graeme Morgan; Karen Byth; Patricia A Mote; Pamela J Provan; Ian O Ellis; Andrew Green; Gillian Lamoury; Peter M Ravdin; Christine L Clarke; Robyn L Ward; Rosemary L Balleine; Nicholas J Hawkins
Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6625-33.
2008: Lori J Goldstein; Robert Gray; Sunil Badve; Barrett H Childs; Carl Yoshizawa; Steve Rowley; Steven Shak; Frederick L Baehner; Peter M Ravdin; Nancy E Davidson; George W Sledge; Edith A Perez; Lawrence N Shulman; Silvana Martino; Joseph A Sparano
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4063-71.
2008: Samuel Wang; Clifton David Fuller; Jong-Sung Kim; Dean Sittig; Charles Thomas; Peter M Ravdin
Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2112-7.
2008: Peter M Ravdin
Hormone replacement therapy and the increase in the incidence of invasive lobular cancer.
Breast disease 2008;30():3-8.
2008: Peter M Ravdin
Overview of randomized trials of systemic adjuvant therapy.
Cancer treatment and research 2008;141():55-62.
2007: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter M Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5287-312.
2007: Donald A Berry; Peter M Ravdin
Breast cancer trends: a marriage between clinical trial evidence and epidemiology.
Journal of the National Cancer Institute 2007;99(15):1139-41.
2007: Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
The decrease in breast-cancer incidence in 2003 in the United States.
The New England journal of medicine 2007;356(16):1670-4.
2007: Constance M Johnson; Joe Ensor; Kristine Broglio; Derek Smolenski; Peter M Ravdin; Christopher Amos; Funda Meric-Bernstam; Abenaa Brewster; Therese Bevers; Banu Arun; Donald Berry
Building a predictive breast cancer risk model.
AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium 2007;():995.
2006: Laura A Siminoff; Nahida H Gordon; Paula Silverman; Thomas Budd; Peter M Ravdin
A decision aid to assist in adjuvant therapy choices for breast cancer.
Psycho-oncology 2006;15(11):1001-13.
2006: Jan Bogaerts; Fatima Cardoso; Marc Buyse; Sofia Braga; Sherene Loi; Jillian A Harrison; Jacques Bines; Stella Mook; Nuria Decker; Peter M Ravdin; Patrick Therasse; Emiel Rutgers; Laura J van 't Veer; Martine Piccart
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
Nature clinical practice. Oncology 2006;3(10):540-51.
2006: Aman U Buzdar; Rowan T Chlebowski; Jack Cuzick; Stephen W Duffy; John Forbes; Walter Jonat; Peter M Ravdin
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Current medical research and opinion 2006;22(8):1575-85.
2006: Richard L Theriault; J Sybil Biermann; Elizabeth Brown; Adam Brufsky; Laurence Demers; Ravinder K Grewal; Theresa Guise; Rebecca D Jackson; Kevin McEnery; Donald A Podoloff; Peter M Ravdin; Charles L Shapiro; Matthew Smith; Catherine Van Poznak
NCCN Task Force Report: Bone Health and Cancer Care.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4 Suppl 2():S1-20; quiz S21-2.
2006: Peter M Ravdin; Gregory Davis
Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables.
Lung cancer (Amsterdam, Netherlands) 2006;52(2):207-12.
2006: Robert W Carlson; Elizabeth Brown; Harold J Burstein; William J Gradishar; Clifford Hudis; Charles L Loprinzi; Eleftherios Paul Mamounas; Edith A Perez; Kathleen Pritchard; Peter M Ravdin; Abram Recht; George Somlo; Richard L Theriault; Eric P Winer; Antonio C Wolff
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4 Suppl 1():S1-26.
2005: Laura F Hutchins; Stephanie J Green; Peter M Ravdin; Danika Lew; Silvana Martino; Martin D Abeloff; Alan P Lyss; Craig Allred; Saul E Rivkin; C Kent Osborne
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8313-21.
2005: Stephen E Jones; J Erban; Beth Overmoyer; G Thomas Budd; Laura F Hutchins; E Lower; Leslie R Laufman; S Sundaram; W J Urba; K I Pritchard; Robert G Mennel; D Richards; S Olsen; M L Meyers; Peter M Ravdin
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5542-51.
2005: Pamela B Peele; Laura A Siminoff; Ying Xu; Peter M Ravdin
Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information.
Medical decision making : an international journal of the Society for Medical Decision Making 2005;25(3):301-7.
2005: Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Gregory J Davis; Stephen K Chia; Karen Gelmon
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2716-25.
2004: Peter M Ravdin
Managing the risk of osteoporosis in women with a history of early breast cancer.
Oncology (Williston Park, N.Y.) 2004;18(11):1385-90, 1393; discussion 1394.
2004: Peter M Ravdin; Gregory J Davis
A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.
Clinical breast cancer 2004;5(4):313-6.
2004: Gary H Lyman; Stephanie J Green; Peter M Ravdin; Charles E Geyer Jr; Christy A Russell; Stanley P Balcerzak; G Thomas Budd; Silvana Martino
A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.
Breast cancer research and treatment 2004;85(2):143-50.
2003: Charles L Loprinzi; Peter M Ravdin
Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1(2):189-96.
2002: John F Forbes; William J Gradishar; Peter M Ravdin
Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?
Breast cancer research and treatment 2002;75 Suppl 1():S37-44; discussion S57-9.
2002: Peter M Ravdin
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Lancet 2002;359(9324):2126-7.
2002: Michael Baum; Peter M Ravdin
Decision-making in early breast cancer: guidelines and decision tools.
European journal of cancer (Oxford, England : 1990) 2002;38(6):745-9.
2001: Luca Gianni; P Dombernowsky; George W Sledge; M Martin; D Amadori; Arbuck Susan; Peter M Ravdin; M Brown; M Messina; David Tuck; C Weil; B Winograd
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(8):1067-73.
2001: R C Bast; Peter M Ravdin; Daniel F Hayes; S Bates; H Fritsche; J M Jessup; Nancy Kemeny; Gershon Y Locker; R G Mennel; Mark R Somerfield
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1865-78.
2001: Peter M Ravdin; Laura A Siminoff; Gregory J Davis; M B Mercer; J Hewlett; N Gerson; H L Parker
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):980-91.
2001: Peter M Ravdin
Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes.
Journal of the National Cancer Institute. Monographs 2001;(30):80-4.
2000: Peter M Ravdin
The use of HER2 testing in the management of breast cancer.
Seminars in oncology 2000;27(5 Suppl 9):33-42.
2000: Richard M Elledge; S Green; R Pugh; D Craig Allred; Gary M Clark; J Hill; Peter M Ravdin; S Martino; C Kent Osborne
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
International journal of cancer. Journal international du cancer 2000;89(2):111-7.
2000: Peter M Ravdin
Overview of randomized trials of systemic adjuvant therapy.
Cancer treatment and research 2000;103():157-81.
1999: Michele De Laurentiis; Sabino De Placido; Angelo Raffaele Bianco; G M Clark; Peter M Ravdin
A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4133-9.
1999: Peter M Ravdin
Should HER2 status be routinely measured for all breast cancer patients?
Seminars in oncology 1999;26(4 Suppl 12):117-23.
1999: Peter M Ravdin
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Seminars in oncology 1999;26(3 Suppl 9):20-3.
1999: T Petit; Cheryl Aylesworth; Howard A Burris; Peter M Ravdin; G Rodriguez; Lon Smith; N Peacock; Leslie Ann Smetzer; R Bellet; Daniel Von Hoff; Eric K Rowinsky
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(2):223-9.
1998: Vicente Valero; Stephen E Jones; Daniel Von Hoff; Daniel J Booser; Robert G Mennel; Peter M Ravdin; Frankie A Holmes; Zia Rahman; M W Schottstaedt; J K Erban; Laura Guerra; R H Earhart; Gabriel N Hortobagyi; Howard A Burris
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3362-8.
1998: Daniel R Ciocca; S Green; Richard M Elledge; Gary M Clark; R Pugh; Peter M Ravdin; D Lew; S Martino; C Kent Osborne
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1263-6.
1998: Sami Diab; Susan G Hilsenbeck; CA de Moor; Gary M Clark; C Kent Osborne; Peter M Ravdin; Richard M Elledge
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1655-60.
1998: Peter M Ravdin; I A Siminoff; J A Harvey
Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):515-21.
1998: Susan G Hilsenbeck; Peter M Ravdin; CA de Moor; Gary C Chamness; C Kent Osborne; Gary M Clark
Time-dependence of hazard ratios for prognostic factors in primary breast cancer.
Breast cancer research and treatment 1998;52(1-3):227-37.
1998: Peter M Ravdin
How can prognostic and predictive factors in breast cancer be used in a practical way today?
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;152():86-93.
1998: M C Roach; V L Boucher; Consuelo Walss-Bass; Peter M Ravdin; Richard Luduena
Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: the beta isotypes of tubulin differ in their cellular distributions within human tissues.
Cell motility and the cytoskeleton 1998;39(4):273-85.
1998: Richard M Elledge; S Green; Daniel R Ciocca; R Pugh; D Craig Allred; Gary M Clark; J Hill; Peter M Ravdin; J O'Sullivan; S Martino; C Kent Osborne
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):7-12.
1998: Peter M Ravdin; N S Callander; G N Hortobagyi
Registry results and high-dose therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):387-8.
1998: René Bruno; D Hille; A Riva; Nicole Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; James R Rigas; Andrew D Seidman; B Chevallier; P Fumoleau; H A Burris; Peter M Ravdin; L B Sheiner
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):187-96.
1997: Peter M Ravdin
Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 7():S7-10.
1997: Peter M Ravdin
Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Seminars in oncology 1997;24(4 Suppl 10):S10-18-S10-21.
1997: Peter M Ravdin; CA de Moor; Susan G Hilsenbeck; M K Samoszuk; P M Vendely; Gary M Clark
Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients.
Cancer letters 1997;116(2):177-83.
1997: Eric K Rowinsky; Lon Smith; G Rodriguez; L White; Ronald L Drengler; Daniel Von Hoff; N Peacock; Cheryl Aylesworth; Howard A Burris; Peter M Ravdin; R Bellet
Docetaxel in combination with fluorouracil: study design and preliminary results.
Oncology (Williston Park, N.Y.) 1997;11(6 Suppl 6):33-5.
1997: Richard M Elledge; S Green; L Howes; Gary M Clark; Melora Berardo; D Craig Allred; R Pugh; Daniel R Ciocca; Peter M Ravdin; J O'Sullivan; S Rivkin; S Martino; C Kent Osborne
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1916-22.
1997: Peter M Ravdin
The international experience with docetaxel in the treatment of breast cancer.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):38-42.
1996: Daniel F Hayes; R C Bast; C E Desch; H Fritsche; Nancy Kemeny; J Milburn Jessup; G Y Locker; J S Macdonald; R G Mennel; Larry Norton; Peter M Ravdin; S Taube; R J Winn
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
Journal of the National Cancer Institute 1996;88(20):1456-66.
1996: Peter M Ravdin
Treatment of patients resistant to anthracycline therapy.
Anti-cancer drugs 1996;7 Suppl 2():13-6.
1996: Peter M Ravdin
A computer program to assist in making breast cancer adjuvant therapy decisions.
Seminars in oncology 1996;23(1 Suppl 2):43-50.
1995: Peter M Ravdin
A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients.
Bulletin du cancer 1995;82 Suppl 5():561s-564s.
1995: Peter M Ravdin
Taxoids: effective agents in anthracycline-resistant breast cancer.
Seminars in oncology 1995;22(6 Suppl 13):29-34.
1995: Peter M Ravdin; Howard A Burris; G Cook; P Eisenberg; M Kane; W A Bierman; J Mortimer; E Genevois; R E Bellet
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2879-85.
1995: Richard M Elledge; R Gray; E Mansour; Y Yu; Gary M Clark; Peter M Ravdin; C Kent Osborne; K Gilchrist; Nancy E Davidson; N Robert
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.
Journal of the National Cancer Institute 1995;87(16):1254-6.
1995: Peter M Ravdin; Gary C Chamness
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.
Gene 1995;159(1):19-27.
1995: Peter M Ravdin; Vicente Valero
Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Seminars in oncology 1995;22(2 Suppl 4):17-21.
1995: Peter M Ravdin
Anthracycline resistance in breast cancer: clinical applications of current knowledge.
European journal of cancer (Oxford, England : 1990) 1995;31A Suppl 7():S11-4.
1994: Peter M Ravdin; Michele De Laurentiis; T Vendely; Gary M Clark
Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators.
Journal of the National Cancer Institute 1994;86(23):1771-5.
1994: Charles L Loprinzi; Peter M Ravdin; Michele De Laurentiis; P Novotny
Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(7):1422-6.
1994: E G Mansour; Peter M Ravdin; L Dressler
Prognostic factors in early breast carcinoma.
Cancer 1994;74(1 Suppl):381-400.
1994: Michele De Laurentiis; Peter M Ravdin
A technique for using neural network analysis to perform survival analysis of censored data.
Cancer letters 1994;77(2-3):127-38.
1994: Peter M Ravdin; A K Tandon; D Craig Allred; Gary M Clark; Suzanne A W Fuqua; S H Hilsenbeck; Gary C Chamness; C Kent Osborne
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):467-74.
1994: Peter M Ravdin
A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy.
Hematology/oncology clinics of North America 1994;8(1):197-211.
1994: D Yee; James G Jackson; Daniel Von Hoff; Peter M Ravdin
Case report: use of insulin-like growth factor-I gene expression to distinguish between breast and ovarian cancer.
The American journal of the medical sciences 1994;307(2):108-11.
1994: C Kent Osborne; M C Sunderland; J A Neidhart; Peter M Ravdin; M D Abeloff
Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(1):43-7.
1994: Michele De Laurentiis; Peter M Ravdin
Survival analysis of censored data: neural network analysis detection of complex interactions between variables.
Breast cancer research and treatment 1994;32(1):113-8.
1994: Gary M Clark; Susan G Hilsenbeck; Peter M Ravdin; Michele De Laurentiis; C Kent Osborne
Prognostic factors: rationale and methods of analysis and integration.
Breast cancer research and treatment 1994;32(1):105-12.
1994: Peter M Ravdin; S Green; James Doroshow; S Martino
Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group study.
Investigational new drugs 1994;12(4):333-6.
1994: Peter M Ravdin
Endocrine treatment of breast cancer.
Current therapy in endocrinology and metabolism 1994;5():556-62.
1993: Peter M Ravdin
Evaluation of cathepsin D as a prognostic factor in breast cancer.
Breast cancer research and treatment 1993;24(3):219-26.
1993: Peter M Ravdin; Gary M Clark; J J Hough; M A Owens; W L McGuire
Neural Network Analysis of DNA flow cytometry histograms.
Cytometry 1993;14(1):74-80.
1992: W L McGuire; A K Tandon; D Craig Allred; Gary C Chamness; Peter M Ravdin; Gary M Clark
Prognosis and treatment decisions in patients with breast cancer without axillary node involvement.
Cancer 1992;70(6 Suppl):1775-81.
1992: Peter M Ravdin; S Green; T M Dorr; W L McGuire; C Fabian; R P Pugh; R D Carter; S E Rivkin; J R Borst; R J Belt
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(8):1284-91.
1992: W L McGuire; A K Tandon; D Craig Allred; Gary C Chamness; Peter M Ravdin; Gary M Clark
Treatment decisions in axillary node-negative breast cancer patients.
Journal of the National Cancer Institute. Monographs 1992;(11):173-80.
1992: Peter M Ravdin; Gary M Clark
A practical application of neural network analysis for predicting outcome of individual breast cancer patients.
Breast cancer research and treatment 1992;22(3):285-93.
1992: Peter M Ravdin; Gary M Clark; Susan G Hilsenbeck; M A Owens; P Vendely; M R Pandian; W L McGuire
A demonstration that breast cancer recurrence can be predicted by neural network analysis.
Breast cancer research and treatment 1992;21(1):47-53.
1991: Peter M Ravdin; K A Havlin; M V Marshall; T D Brown; J M Koeller; John Kuhn; G Rodriguez; Daniel Von Hoff
A phase I clinical and pharmacokinetic trial of hepsulfam.
Cancer research 1991;51(23 Pt 1):6268-72.
1990: D L Trump; Peter M Ravdin; Ernest C Borden; C F Magers; J K Whisnant
Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.
Journal of biological response modifiers 1990;9(1):108-11.
1988: Peter M Ravdin; N F Fritz; D C Tormey; V C Jordan
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
Cancer research 1988;48(4):1026-9.
1988: Peter M Ravdin; V C Jordan
Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the rat.
Life sciences 1988;43(2):117-23.
1987: Peter M Ravdin; M van Beurden; N F Fritz; S P Robinson; V C Jordan
Effect of submandibular gland removal on carcinogen induced rat mammary tumors.
European journal of cancer & clinical oncology 1987;23(4):449-50.
1987: Peter M Ravdin; M van Beurden; V C Jordan
Estrogenic effects of phenolphthalein on human breast cancer cells in vitro.
Breast cancer research and treatment 1987;9(2):151-4.